Evoluzione delle lesioni demielinizzanti mediante esami seriati di RM

O. Ciccarelli, A. Paolillo, E. Giugni, M. Gherardi, A. Mancini, G. Luccichenti, C. Gasperini, C. Pozzilli, S. Bastianello

Research output: Contribution to journalArticle

Abstract

Aim of the study was to monitor the natural history of new demyelinating lesions by means of serial Magnetic Resonance Imaging (MRI). Sixty-eight relapsing-remitting multiple sclerosis (MS) patients were monthly examined by enhanced T1 weighted and T2 weighted SpinEcho images. New enhancing lesions, which were not present on the first scan, were considered as starting point. Then after the evolution of these lesions were followed for five monthly scans. Out of the 63 new enhancing lesions, 26 (40%) showed persisting enhancement at 1-month scan, and 12 (19%) at 2-month scan; 4 (6%) lesions presented a fluctuating recurrent enhancement during the follow-up. All 63 new enhancing lesions had a corresponding area of abnormality on 72 weighted images. At first follow-up scan 62 (98%) and 21 (33%) of the new enhancing lesions were seen as T2 hyperintensity and T1 hypointensity respectively. At the last follow-up scan, T2 hyperintensity was observed in 58 (92%) of the new enhancing lesions, and T1 hypointensity in 26 (41%) of them. Five (8%) of the new enhancing lesions disappeared at the last scan in both T2 and T1 weighted images. This study documents that the evolution of new enhancing lesions is related to the different phases of demyelinating process.

Original languageItalian
Pages (from-to)11-17
Number of pages7
JournalGiornale di Neuropsicofarmacologia
Volume20
Issue number1
Publication statusPublished - Jan 1998

ASJC Scopus subject areas

  • Neuroscience(all)
  • Pharmaceutical Science
  • Pharmacology
  • Neuropsychology and Physiological Psychology

Cite this

Ciccarelli, O., Paolillo, A., Giugni, E., Gherardi, M., Mancini, A., Luccichenti, G., ... Bastianello, S. (1998). Evoluzione delle lesioni demielinizzanti mediante esami seriati di RM. Giornale di Neuropsicofarmacologia, 20(1), 11-17.

Evoluzione delle lesioni demielinizzanti mediante esami seriati di RM. / Ciccarelli, O.; Paolillo, A.; Giugni, E.; Gherardi, M.; Mancini, A.; Luccichenti, G.; Gasperini, C.; Pozzilli, C.; Bastianello, S.

In: Giornale di Neuropsicofarmacologia, Vol. 20, No. 1, 01.1998, p. 11-17.

Research output: Contribution to journalArticle

Ciccarelli, O, Paolillo, A, Giugni, E, Gherardi, M, Mancini, A, Luccichenti, G, Gasperini, C, Pozzilli, C & Bastianello, S 1998, 'Evoluzione delle lesioni demielinizzanti mediante esami seriati di RM', Giornale di Neuropsicofarmacologia, vol. 20, no. 1, pp. 11-17.
Ciccarelli O, Paolillo A, Giugni E, Gherardi M, Mancini A, Luccichenti G et al. Evoluzione delle lesioni demielinizzanti mediante esami seriati di RM. Giornale di Neuropsicofarmacologia. 1998 Jan;20(1):11-17.
Ciccarelli, O. ; Paolillo, A. ; Giugni, E. ; Gherardi, M. ; Mancini, A. ; Luccichenti, G. ; Gasperini, C. ; Pozzilli, C. ; Bastianello, S. / Evoluzione delle lesioni demielinizzanti mediante esami seriati di RM. In: Giornale di Neuropsicofarmacologia. 1998 ; Vol. 20, No. 1. pp. 11-17.
@article{fc280224ff73409cb80d6595507772c9,
title = "Evoluzione delle lesioni demielinizzanti mediante esami seriati di RM",
abstract = "Aim of the study was to monitor the natural history of new demyelinating lesions by means of serial Magnetic Resonance Imaging (MRI). Sixty-eight relapsing-remitting multiple sclerosis (MS) patients were monthly examined by enhanced T1 weighted and T2 weighted SpinEcho images. New enhancing lesions, which were not present on the first scan, were considered as starting point. Then after the evolution of these lesions were followed for five monthly scans. Out of the 63 new enhancing lesions, 26 (40{\%}) showed persisting enhancement at 1-month scan, and 12 (19{\%}) at 2-month scan; 4 (6{\%}) lesions presented a fluctuating recurrent enhancement during the follow-up. All 63 new enhancing lesions had a corresponding area of abnormality on 72 weighted images. At first follow-up scan 62 (98{\%}) and 21 (33{\%}) of the new enhancing lesions were seen as T2 hyperintensity and T1 hypointensity respectively. At the last follow-up scan, T2 hyperintensity was observed in 58 (92{\%}) of the new enhancing lesions, and T1 hypointensity in 26 (41{\%}) of them. Five (8{\%}) of the new enhancing lesions disappeared at the last scan in both T2 and T1 weighted images. This study documents that the evolution of new enhancing lesions is related to the different phases of demyelinating process.",
keywords = "Demyelinating Lesions, Magnetic Resonance Imaging, Multiple Sclerosis",
author = "O. Ciccarelli and A. Paolillo and E. Giugni and M. Gherardi and A. Mancini and G. Luccichenti and C. Gasperini and C. Pozzilli and S. Bastianello",
year = "1998",
month = "1",
language = "Italian",
volume = "20",
pages = "11--17",
journal = "Giornale di Neuropsicofarmacologia",
issn = "0391-9048",
publisher = "CIC Edizioni Internazionali s.r.l.",
number = "1",

}

TY - JOUR

T1 - Evoluzione delle lesioni demielinizzanti mediante esami seriati di RM

AU - Ciccarelli, O.

AU - Paolillo, A.

AU - Giugni, E.

AU - Gherardi, M.

AU - Mancini, A.

AU - Luccichenti, G.

AU - Gasperini, C.

AU - Pozzilli, C.

AU - Bastianello, S.

PY - 1998/1

Y1 - 1998/1

N2 - Aim of the study was to monitor the natural history of new demyelinating lesions by means of serial Magnetic Resonance Imaging (MRI). Sixty-eight relapsing-remitting multiple sclerosis (MS) patients were monthly examined by enhanced T1 weighted and T2 weighted SpinEcho images. New enhancing lesions, which were not present on the first scan, were considered as starting point. Then after the evolution of these lesions were followed for five monthly scans. Out of the 63 new enhancing lesions, 26 (40%) showed persisting enhancement at 1-month scan, and 12 (19%) at 2-month scan; 4 (6%) lesions presented a fluctuating recurrent enhancement during the follow-up. All 63 new enhancing lesions had a corresponding area of abnormality on 72 weighted images. At first follow-up scan 62 (98%) and 21 (33%) of the new enhancing lesions were seen as T2 hyperintensity and T1 hypointensity respectively. At the last follow-up scan, T2 hyperintensity was observed in 58 (92%) of the new enhancing lesions, and T1 hypointensity in 26 (41%) of them. Five (8%) of the new enhancing lesions disappeared at the last scan in both T2 and T1 weighted images. This study documents that the evolution of new enhancing lesions is related to the different phases of demyelinating process.

AB - Aim of the study was to monitor the natural history of new demyelinating lesions by means of serial Magnetic Resonance Imaging (MRI). Sixty-eight relapsing-remitting multiple sclerosis (MS) patients were monthly examined by enhanced T1 weighted and T2 weighted SpinEcho images. New enhancing lesions, which were not present on the first scan, were considered as starting point. Then after the evolution of these lesions were followed for five monthly scans. Out of the 63 new enhancing lesions, 26 (40%) showed persisting enhancement at 1-month scan, and 12 (19%) at 2-month scan; 4 (6%) lesions presented a fluctuating recurrent enhancement during the follow-up. All 63 new enhancing lesions had a corresponding area of abnormality on 72 weighted images. At first follow-up scan 62 (98%) and 21 (33%) of the new enhancing lesions were seen as T2 hyperintensity and T1 hypointensity respectively. At the last follow-up scan, T2 hyperintensity was observed in 58 (92%) of the new enhancing lesions, and T1 hypointensity in 26 (41%) of them. Five (8%) of the new enhancing lesions disappeared at the last scan in both T2 and T1 weighted images. This study documents that the evolution of new enhancing lesions is related to the different phases of demyelinating process.

KW - Demyelinating Lesions

KW - Magnetic Resonance Imaging

KW - Multiple Sclerosis

UR - http://www.scopus.com/inward/record.url?scp=0032379912&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032379912&partnerID=8YFLogxK

M3 - Articolo

AN - SCOPUS:0032379912

VL - 20

SP - 11

EP - 17

JO - Giornale di Neuropsicofarmacologia

JF - Giornale di Neuropsicofarmacologia

SN - 0391-9048

IS - 1

ER -